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Objectives: To characterise Chorionic Plate Artery (CPA) function in maternal obesity, and investigate
whether leptin exposure reproduces the obese CPA phenotype in normal-BMI women.
Study design: CPA responses to the thromboxane-A2 mimetic U46619 (pre/post leptin incubation), to the
nitric oxide donor sodium nitroprusside (SNP) and the occurrence of tone oscillations (pre/post leptin
incubation) were assessed in 46 term placentas from women of normal (18.5e24.9) or obese (>30) Body
Mass Index (BMI).
Outcome measures: Area Under the dose response Curve (AUC), maximum response (Vmax), sensitivity
(EC50) to U46619 (pre/post leptin) and SNP; average vessel tone, oscillation amplitude and frequency
(pre/post leptin).
Results: U46619 vasoconstriction was similar between BMI categories (p > 0.05), however vasodilatation
to SNP was reduced in obesity (AUC p ¼ 0.02, Vmax p ¼ 0.04) compared to normal-BMI women. Leptin
incubation altered responses to U46619 in both normal-BMI (EC50 at 100 ng/ml leptin; p < 0.05) and
obese women (AUC at 50 ng/ml; p < 0.05) but vasomotion was unaffected (p > 0.05).
Conclusions: Maternal obesity is associated with altered placental vascular function which may adversely
affect placental oxygen and nutrient transport, placing the fetus at risk. Leptin incubation altered CPA
vascular function but did not reproduce the obese phenotype.
 2013 Elsevier Ltd. Open access under CC BY-NC-ND license.1. Introduction
The obesity epidemic is one of the most signiﬁcant challenges to
21st century health. In 2008 59% of the obese population world-
wide was female [1]. Recent ﬁgures show that in North-West En-
gland nearly 20% of women registering for antenatal care are obese
[2,3] as deﬁned by Body Mass Index (BMI  30 kg/m2; weight (kg)/
height (m)2) [4]. Maternal obesity increases the risk of a range of
complications including fetal growth restriction (FGR) [5], fetal
overgrowth [6], and related complications including stillbirth, birth
injury and intervention in labour [7]. Indeed infants stillborn to
obese mothers are commonly of low-normal birth weight [5],
suggesting that failure to achieve individual growth potential
despite remaining within an arbitrary population “normal” weight
range may have contributed to their demise. Both FGR and large for
gestational age (LGA) are major causes of morbidity and mortality
with long-term health consequences [8].h Research Centre, The Uni-
xford Road, Manchester M13
: þ44 (0)161 701 6971.
.uk (C.E. Hayward).
-NC-ND license.Fetal growth is dependent on a number of factors, particularly
oxygen and nutrient delivery via maternal and fetoplacental blood
supplies. Susceptibility to FGR or LGA birth could arise from
reduced or elevated uteroplacental blood ﬂow respectively. Chori-
onic plate arteries (CPAs) have the features of resistance arteries in
other circulations [9] and thus have the potential to regulate tone
resistance in the placental circulation. Placental vascular dysfunc-
tion in FGR pregnancies is observed in vivo by umbilical artery
Doppler measurements [10], and in vitro when using wire myog-
raphy to measure vascular responses to agonists [11] and examine
tone oscillations (rhythmic vasoconstriction and vasodilation)
which are thought to acutely modulate local blood ﬂow in the
placenta and determine end organ perfusion [12]. However, vas-
cular function has not been extensively assessed in maternal obe-
sity or fetal overgrowth, with ﬁndings of umbilical artery Doppler
studies often being compounded by co-occurrence of gestational
diabetes [13,14]. There have been no previous studies of placental
chorionic artery function in relation to maternal obesity.
Increasing BMI correlates with increased adipose tissue mass
[15]. Adipose tissue represents a highly active endocrine organ
which secretes prothrombotic and proinﬂammatory substances e.g.
leptin, endothelin-1, tumour necrosis factor (TNF)-a, plasminogen
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protective factors, such as adiponectin [16]. In obesity, the
increased adipose tissue mass results in derangements in a number
of these circulating hormones and factors, often referred to as
adipokines, which may alter homeostatic regulation of uteropla-
cental vascular tone and hence transplacental oxygen and nutrient
delivery. This altered hormonal environment has been proposed as
a potential link between obesity and the increased risk of disorders
of vascular endothelial origin [17]. In particular a key adipokine,
leptin is known to have vasoactive properties [18]. Altered umbil-
ical cord blood leptin concentrations are observed in pregnancies
associated with maternal obesity [19] and in pregnancies resulting
in birth of FGR or LGA infants [20].
Aberrant fetal growth in maternal obesity might arise as
a consequence of dysregulated nutrient delivery to the fetus via
altered placental blood ﬂow. This study tested the hypotheses
that (a) maternal obesity is associated with altered function of
small CPAs and (b) leptin exposure replicates the obese CPA
phenotype.
2. Materials and methods
2.1. Ethical information
North West (Haydock Park) Research Ethics Committee (Ref: 08/H1010/55)
approved the study. Written informed consent was obtained from all women.
2.2. Participants and placental collection
Participants were identiﬁed upon admission to hospital for delivery at 37e42
weeks gestation (N ¼ 46). Women with diabetes and hypertension (pre-existing
or gestational) or other maternal or fetal conditions, including antenatally diag-
nosed SGA or LGA pregnancies, were excluded. First trimester maternal BMI was
used to categorise participants as normal-BMI (18.5e24.9 kg/m2) or obese (30 kg/
m2). An individualised birth weight ratio (IBR) was calculated for each infant using
Gestation-Related Optimal Weight software (Customised Weight Centile Calculator
v5.12/6.2 2009; www.gestation.net) taking into account maternal variables, ges-
tation and gender; use of IBR has been shown to improve identiﬁcation of preg-
nancies with aberrant fetal growth [21]. Infants were categorised as small for
gestational age (SGA; IBR <10th centile), appropriate for gestational age (AGA; IBR
10the90th centile), or LGA (IBR >90th centile). Whilst antenatally diagnosed cases
of SGA or LGA were excluded from the study (as antenatal/intrapartum manage-
ment of these pregnancies may have been affected by this diagnosis, including
elective delivery at a relatively earlier gestation and the potential administration of
corticosteroids) those postnatally diagnosed SGA or LGA pregnancies were not
excluded.
2.3. Wire myography
Placentas were collected within 30 min of delivery. Chorionic plate biopsies
were placed into physiologic salt solution (PSS; 119 mM NaCl, 25 mM NaHCO3,
4.69 mM KCl, 2.4 mM MgSO4, 1.6 mM CaCl2, 1.18 mM KH2PO4, 6.05 mM glucose,
0.034mM EDTA; pH 7.4). Small CPA branches (100e500 mm)were dissected, cut into
2 mm lengths and mounted on two 40 mm steel wires in a Danish Myotechnology
M610 wire myograph (Danish Myotech, Aarhus, Denmark) ﬁlled with PSS gassed
with 5%CO2/5%O2/N2 (Normal-BMI N ¼ 17 placentas, n ¼ 77 vessels; obese N ¼ 13
placentas, n ¼ 65 vessels). Arteries were normalised to an internal diameter of 0.9 of
L5.1kPa equivalent to an intraluminal pressure of 25 mm Hg, as described previously
[22] (Myodaq software version 2.02; Danish Myotech Aarhus). Following equili-
bration (20e30 min), the bath solution was changed to KPSS (11 mM NaCl, 25 mM
NaHCO3, 120 mM KCl, 2.4 mM MgSO4, 1.6 mM CaCl2, 1.18 mM KH2PO4, 6.05 mM
glucose, 0.034mM EDTA; pH 7.4) to assess vessel viability. After repeated washing to
baseline tone, constriction was assessed using incremental doses of the throm-
boxane-A2 mimetic U46619 (1010e105.7 M; response recorded at plateau or after
ﬁveminutes if plateau not reached). Arteries were againwashed and the experiment
proceeded using one of the following protocols (Fig. 1).
2.4. Protocol 1: Endothelium-independent relaxation
CPAs from normal-BMI (N ¼ 8 placentas, n ¼ 28 vessels) and obese (N ¼ 10
placentas, n ¼ 38 vessels) womenwere pre-constricted with an EC80 (concentration
required to achieve 80% of maximal constriction for each vessel) concentration of
U46619 for 20 min, then exposed to incremental doses of the nitric oxide donor,
sodium nitroprusside (SNP; 1010e104 M; intervals as above).2.5. Protocol 2: Effect of leptin on vessel constriction
Placentas utilized for protocol 2 were all collected from women who had
delivered AGA babies. CPAs from normal-BMI (N ¼ 12 placentas, n ¼ 12 vessels for
control and each individual leptin concentration) and obese (N ¼ 7 placentas, n ¼ 7
vessels for control and each individual leptin concentration) womenwere incubated
for 1 h with vehicle diluent without leptin or 20, 50 or 100 ng/ml leptin (recon-
stituted in 0.5 ml 15 mMHCl and 0.3 ml 7.5 mMNaOH) to represent an internal time
control, normal circulating levels of leptin, obese circulating levels of leptin and
supra-physiological levels of leptin respectively in maternal serum and cord blood
[23e25]. Following incubation, the U46619 dose response curve was repeated.
2.6. Protocol 3: Effect of leptin on endothelial function
Tone oscillations (rhythmic vasoconstriction and vasodilation) which are a fea-
ture of CPA function in vitro and are altered in FGR [12], are thought to be modulated
by vascular endothelium and have the potential to acutely modulate local blood
ﬂow. These were assessed in placentas from normal-BMI (N ¼ 11 placentas, n ¼ 14
vessels for control and each individual leptin concentration) delivering AGA infants
using a method adapted from Sweeney and colleagues [12] (Fig. 2). CPAs were
exposed to a sub-maximal concentration (30 nM) of U46619 for 30 min to induce
oscillations, followed by 15 min incubation with the endothelium-dependent vas-
odilator bradykinin (ﬁnal concentration 1 mM; BK). The arteries were then washed
with PSS and incubated for 1 h with vehicle diluent or 20, 50 or 100 ng/ml leptin.
Following incubation, exposure to U46619 and BK was repeated.
2.7. General chemicals
Chemicals and pharmacological agents were purchased from SigmaeAldrich
(Poole, Dorset, UK) or BDH (Poole, Dorset, UK).
2.8. Statistics
Data were analysed using GraphPad Prism 5 for Windows (GraphPad Software,
San Diego, CA) according to maternal obesity status; subgroup analyses were per-
formed for AGA pregnancies and for fetal gender. N represents the number of pla-
centas studied; n represents the number of vessels.
Vessel tone was expressed as active effective pressure (kPa): tension (mN/
mm)  [diameter (mm)/2000]. Area Under the dose response Curve (AUC; arbitrary
units; calculated as the area between the dose response curve and the line of y ¼ 0),
maximum response (Vmax; in kPa for U46619 and percentage change from baseline
pre-constriction for SNP irrespective of the agonist dose at which that response
occurred) and sensitivity (EC50; in nM for concentration of agonist required to achieve
50% maximal response) were calculated for each artery and averaged per placenta.
Fluctuations in vascular tone were observed in CPAs when contraction was
stimulated with a sub-maximal dose (30 nM) of U46619 and subsequently after
addition of BK. These tone ﬂuctuations were deﬁned as oscillations when the
amplitude (change in tone from top to bottom) exceeded 10% of themaximum (peak)
constriction to 30 nM U46619. The number of oscillations in the ﬁnal 15 min of the
U46619 incubation was counted and expressed as a frequency (min1). Maximum
response (Vmax) to BK, oscillation amplitude (percentage of peakU46619 constriction)
and oscillation frequency were compared pre/post-leptin incubation for each artery.
Categorical data are presented as frequencies and tested by c2 analysis, con-
tinuous data are presented as medians (range in parentheses) and analysed by
Mann-Whitney U tests; subgroup analysis of AGA infants was also performed to
exclude the possibility of confounding effects of infant growth phenotypes. Paired
data (pre/post-leptin incubation) were compared using Wilcoxon matched-pairs
signed rank test (for AUC, Vmax and EC50 to U46619) or Friedman test (for oscil-
lation and BK data). Statistical signiﬁcance was set at p < 0.05.
Based on a previous study examining CPA vasoconstriction to U46619 in dif-
fering oxygen concentrations [26], we calculated that 10 patients/group would be
required to detect a similar magnitude of difference in maximal contraction (mean
difference 4.0 kPa, standard deviation 2.8 kPa) with power of 90% and signiﬁcance
level of 5%.
3. Results
3.1. Demographic and outcome data
Clinical data are presented in Table 1. Other than for BMI,
maternal characteristics were comparable between groups. Infants
of obese women were more frequently male, had higher birth
weights and IBRs, and were more likely to be LGA compared to
infants of normal-BMI women. Subgroup analysis by fetal gender
revealed no signiﬁcant difference in birth weight, IBR or rates of
macrosomia and LGA betweenmale and female offspring (p> 0.05)
Fig. 1. Study protocol.
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however female offspring of obese mothers were statistically larger
in terms of both birth weight (p ¼ 0.002) and IBR (p ¼ 0.005).
3.2. CPA constriction is unaffected by maternal BMI
U46619-induced vasoconstriction in the obese cohort did not
differ to that from normal-BMI women (Fig. 3aec), although
maternal obesity was associated with a trend towards increased
Vmax which failed to reach signiﬁcance (p ¼ 0.08).
To ensure there were no confounding effects of infant birth
weight on the relationship between maternal BMI and placental
vascular function, comparisons were made between AGA births in
the three BMI cohorts; AUC, Vmax and EC50 values to U46619 were
comparable (p > 0.05) between groups and between male and fe-
male offspring.
3.3. Protocol 1: Raised maternal BMI impairs placental CPA
vasodilatation
CPA vasodilatation to SNP in the obese cohort was signiﬁcantly
reduced compared to normal-BMI women (Fig. 4aeb). The dose
response curve to SNP was signiﬁcantly non-sigmoidal in 50% of
all obese participants (in keeping with studies in FGR placentas)
and therefore an SNP EC50 value could not be calculated for theseplacentas. Examination of only the vasodilatory phase of SNP
dose response curves also failed to ﬁt a sigmoidal curve. Con-
sequently sensitivity to SNP has not been compared between
cohorts. In analysing only AGA pregnancies SNP Vmax remained
signiﬁcantly different between normal-BMI and obese cohorts
[53.9% (36.5e62.5) vs. 27.7% (17.5e40.1) respectively, p ¼ 0.03].
No statistically signiﬁcant difference was observed between fetal
genders in terms of AUC or Vmax (p > 0.05) and SNP dose response
curves remained non-sigmoidal.
3.4. Protocol 2: Leptin exposure impairs CPA vasoconstriction
Leptin exposure data on CPA constriction are summarised in
Table 2. U46619-induced constriction was unaffected by exper-
imental duration (p> 0.05, data not shown). In normal-BMIwomen
sensitivity to U46619 signiﬁcantly decreased (higher EC50) post-
incubation with 100 ng/ml leptin (p < 0.01) but other parameters
were unaffected by leptin incubation. In the obese cohort, U46619
AUC was signiﬁcantly reduced post-incubation with 50 ng/ml lep-
tin (p < 0.05) but not at higher leptin concentrations.
3.5. Protocol 3: No effect of leptin on tone oscillations in CPAs
Tone oscillations were observed in 61% of CPAs prior to leptin
incubation. Peak constriction and average tone to U46619 (Fig. 2)
Table 1
Demographic, biophysical and obstetric data for participants. Data are median
(range) unless stated otherwise. Abbreviations; IBR, individualised birth weight
ratio; BMI, body mass index; SGA, small for gestational age; LGA, large for gesta-
tional age. SGA is deﬁned as IBR < 10th centile, LGA is deﬁned as IBR > 90th centile
and macrosomia deﬁned as birth weight >4 kg.
Fig. 2. Examples of original tracings illustrating U46619-induced tone oscillations with
1 mM bradykinin (BK) added at the end of the exposure period. The peak constriction
(PC) and average tone over the last 15 min of the U46619 constriction were calculated
for each CPA. Oscillations during the U46619 constriction were deﬁned as a change in
tone (peak to trough) of >10% compared to the PC. Mean amplitude (OA) and fre-
quency (min1) of oscillations to U46619 were calculated for each artery. The max-
imum response, average tone, oscillation amplitude and frequency over 15 min were
calculated for BK exposure.
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with amplitude and frequency of 24.6% (0.6e70.7%) and 0.05 per
min (0.02e0.7 per min) respectively. BK exposure signiﬁcantly
reduced peak constriction by 50.5% (14.4e94.7%; Vmax; p < 0.0001)
and increased oscillation amplitude to 47.7% (12.5e90.9%) of peak
U46619 constriction (p < 0.05) but had no signiﬁcant effect on
oscillation frequency (0.07 per min [0.03e2.0 per min]). CPA tone,
oscillation amplitude and frequency or relaxation to BK were un-
affected by leptin exposure (Table 3).Category Normal (n ¼ 26) Obese (n ¼ 20) p
Age: Years 29 (16e42) 30 (20e39) ns
Caucasian: Number (%) 20 (77) 12 (60) ns
Parity 1 (0e3) 1 (0e4) ns
Smoker: Number (%) 3 (12) 1 (5) ns
BMI at booking: Kg/m2 22.5 (18.5e24.7) 34.2 (30.4e49.6) <0.05
Gestation: Weeks 39þ1 (37þ6e41þ4) 39þ2 (38þ0e41þ6) ns
Laboured: Number (%) 4 (15.4) 2 (10.0) ns
Caesarean: Number (%) 22 (84.6) 18 (90.0) ns
Previous Caesarean section:
Number (%)
14 (51.9%) 10 (50.0%) ns
Birth weight: Grams 3215 (2500e3840) 3790 (2880.0e4850.0) <0.05
IBR: Centile 40 (4e99) 76 (5e100) <0.05
Male infant: Number (%) 9 (35) 13 (68) <0.05
SGA: Number (%) 3 (12) 1 (5) ns
LGA: Number (%) 2 (8) 5 (25) <0.05
Macrosomia: Number (%) 0 (0) 5 (25) <0.054. Discussion
This study demonstrates altered placental vascular reactivity
in maternal obesity and is the ﬁrst to examine the effect of leptin
on placental vascular function. U46619-induced CPA constriction
was unaffected by maternal BMI whilst SNP induced CPA
relaxation was impaired in obesity. These data indicate that term
placental vascular function is impaired in women who commence
pregnancy with an increased BMI. It is interesting to note
that these differences in vascular function between placentas of
normal-BMI and obese women have been observed in preg-
nancies resulting predominantly in AGA offspring and that in
this cohort (although underpowered to study the effect of
fetal gender in detail) maternal obesity appears to promotegrowth of female fetuses but not of male fetuses. We believe that
this may result (in part) from the fetus compensating for adverse
intrauterine conditions, regulating its own growth despite the
adverse maternal environment.
If altered CPA reactivity translates to a less vasodilated pheno-
type as suggested by the ﬁndings of this study, aberrant placental
blood ﬂow and lower birth weights would be expected. However,
the impairment of CPA vasodilatation to SNP contrasts with the
enhanced CPA vasodilatation in response to this endothelium-
independent vasodilator observed in idiopathic FGR pregnancies
[11]. We hypothesise that this may have an effect on organ perfu-
sion and alter the homeostatic regulation of blood pressure and
blood ﬂow in the offspring, predisposing to cardiovascular disease
in later life [27].
In keeping with other studies, CPAs from both BMI cohorts
demonstrated the characteristic biphasic response to SNP; a vaso-
dilatation followed by vasoconstriction with doses above 106 M
(Fig. 4a) [11,26]. The mechanisms underlying this have not been
explored as yet. Although impaired CPA vasodilatation may be
expected to reduce nutrient transfer across the placenta by
impairing placental blood ﬂow and hence lead to reduced fetal
growth, in this small cohort there was a high incidence of LGA birth
amongst obese women, despite exclusion of pregnancies compli-
cated by antenatally diagnosed aberrant fetal growth. This dem-
onstrates that the link between CPA tone, placental blood ﬂow and
fetal growth is not simple.
Wire myography studies suggest that isolated CPAs are rela-
tively unresponsive to endothelial-dependent agonists, such as
acetylcholine and BK, following EC80 or Vmax doses of U46619 [28].
However, in pressure myography studies of CPAs, ﬂow-induced
nitric oxide release induces vasodilation which suggests that
shear-stress promotes nitric oxide release from the endothelium
that can inﬂuence basal tone [29]. Here, we replicated the ﬁndings
of Sweeney and colleagues who demonstrated that in CPAs exposed
to a sub-maximal dose of U46619, vascular tone could be reduced
by BK (Fig. 2; Table 3), and tone oscillations (vasomotion) could be
observed [12]. Vasomotion (rhythmic oscillations in vascular tone)
has been observed in many vascular beds but its function has not
been fully elucidated. The general consensus is that oscillations
occur via interactions between the endothelium and underlying
smooth muscle to promote efﬁcient blood ﬂow to optimise end-
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Fig. 3. Effect of maternal BMI on chorionic plate artery vasoconstriction. Vasoconstriction response of CPAs to the thromboxane-A2 mimetic U46619 was unaltered between BMI
cohorts: a) Dose response curves; Area under the curve (AUC; p > 0.05). b) Maximal response (Vmax; p > 0.05). c) Sensitivity (EC50; p > 0.05).
C.E. Hayward et al. / Placenta 34 (2013) 281e287 285organ perfusion [30]. These ﬁndings further support a role for the
endothelium in the control of basal CPA tone.
It is possible that altered circulating adipokine concentrations in
obesity may contribute to altered placental vascular reactivity.
Hyperleptinemia, as observed in obese humans and in animal
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Fig. 4. Effect of maternal obesity on chorionic plate artery vasodilation. Vasodilation resp
obesity: a) Dose response curve (AUC; p ¼ 0.02). b) Maximal response (Vmax; p ¼ 0.04).
Table 2
Leptin exposure impairs chorionic plate artery vasoconstriction. Demonstrating the eff
U46619. Abbreviations; TC, time control. Data are median and (range). *P < 0.05, **P < 0
BMI
Category
Leptin concentration
ng/ml
AUC arbitrary units Vmax
Pre Post Pre
Normal 0 [TC] 13.0 (6.8e28.1) 13.5 (3.2e23.0) 9.0
50 8.4 (3.7e35.5) 9.5 (4.3e28.8) 7.3
100 13.4 (7.7e33.4) 9.2 (6.9e39.3) 8.2
Obese 0 [TC] 13.2 (7.9e38.3) 16.0 (5.7e31.0) 10.1
50 20.0 (11.0e35.6) 13.4* (9.9e21.4) 14.0
100 14.8 (9.7e28.7) 18.2 (9.9e28.8) 10.3nitric oxide bioavailability and increased oxidative stress in the
systemic circulation [31]. Leptin receptors are present in the pla-
centa and on vascular endothelial cells [31,32] indicating that the
placenta has the potential to detect/respond to differing leptin
concentrations and this may offer a mechanism by which adipo-
kines are potential dysregulators of fetoplacental blood ﬂow. WeNormal Obese
0
20
40
60
80
100
R
ela
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(%
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b
onse of CPAs to the nitric oxide donor sodium nitroprusside is impaired by maternal
ects of vessel incubation with differing concentrations of leptin on constriction to
.01 pre/post-incubation.
kPa EC50 nM
Post Pre Post
(5.5e15.1) 8.5 (6.1e16.8) 105.7 (9.0e258.2) 85.9 (5.3e679.2)
(2.8e22.5) 7.7 (3.4e23.5) 82.5 (25.4e347.5) 113.8 (1.8e382.8)
(6.0e21.3) 7.8 (6.0e24.8) 79.4 (11.1e137.4) 224.4** (43.3e466.7)
(5.6e22.2) 10.1 (6.1e22.8) 61.1 (14.4e135.2) 56.6 (42.0e358.1)
(9.2e27.1) 10.9 (5.1e13.8) 89.1 (27.5e161.1) 59.0 (20.9e769.1)
(7.7e18.0) 9.8 (8.9e17.7) 60.1 (37.8e349.0) 66.4 (12.1e343.6)
Table 3
Chorionic plate artery vasomotion in normal-BMI women is unaltered by leptin exposure. No parameters studied were altered by treatment with leptin (p > 0.05). Abbre-
viations; TC, time control. Data are median (range).
Leptin concentration
ng/ml
Peak constriction kPa Average tone kPa Amplitude % peak
U46619 constriction
Frequency min1 BK Vmax % peak
U46619 constriction
0 (TC) 4.5 (1.9e10.9) 3.0 (1.4e9.6) 29.2 (11.2e133.3) 0.1 (0.03e0.17) 63.2 (21.8e93.8)
50 5.7 (1.5e13.0) 3.4 (1.0e8.9) 25.3 (11.0e40.3) 0.1 (0.03e0.73) 55.7 (19.3e193.3)
100 5.5 (1.4e16.2) 3.6 (0.7e10.1) 41.7 (22.2e97.0) 0.07 (0.03e0.13) 40.4 (16.4e87.9)
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constriction in response to a thromboxane-A2 mimetic but had no
effect on endothelial-dependent CPA relaxation induced by BK or
on tone oscillations in CPAs. Our ﬁndings therefore contradict
previous studies [18,33] that suggest a direct or acute role of leptin
in modulation of CPA endothelial function, but agree with other
studies [34] which indicate leptin affects endothelial-independent
mechanisms.
The differences demonstrated in CPA phenotype between
obese and leptin-treated normal-BMI placentas require further
mechanistic study. It is noteworthy that maximal leptin effects
were observed at differing concentrations in CPAs from normal-
BMI compared to obese women (100 ng/ml vs. 50 ng/ml) sug-
gestive of altered placental artery sensitivity to leptin. We
hypothesise that the reasons for the failure of leptin exposure
in vitro to reproduce the obese CPA phenotype may be related to
differences in the duration of leptin exposure in vitro compared
with in utero and co-exposure to deranged levels of other adipo-
kines. It is unlikely that leptin alone would be the sole link be-
tween obesity and increased susceptibility to poor pregnancy
outcome. Nonetheless, these results add to a growing literature
[18,33,35] suggesting that leptin has a role to play in regulating
vascular function.
4.1. Study limitations
Study participants were identiﬁed and recruited at admission
for delivery. The majority of participants were delivered by elective
Caesarean section as these women were pain-free at the time of
approach and able to give informed consent to research partic-
ipation. The decision for Caesarean section has been subtextually
inﬂuenced by maternal or clinician estimated fetal size and may
account for the high rate of SGA and LGA births observed in this
study compared with the general population. Mode of delivery has
previously been studied using a similar experimental protocol in
a cohort of 145 pregnancies and was shown to have no inﬂuence on
chorionic plate vascular reactivity [36]. Therefore we believe our
ﬁndings truly reﬂect the effect of maternal obesity on CPA physi-
ology rather than consequences of mode of delivery.
As a non-interventional study in which participants were
enrolled at admission for delivery, and obesity itself is not in itself
an indication for routine fetal growth and umbilical artery Doppler
surveillance of the pregnancy in the United Kingdom; data on
in vivo placental vascular function is lacking for the majority of
study participants. As such we are unable to link our ex vivo vas-
cular studies to in utero umbilical artery Doppler resistance pa-
rameters however the relationship between wire myography and
Doppler parameters is debated [11,37] and is itself in need of fur-
ther examination.
4.2. Future perspectives
The preponderance of male offspring amongst the obese
women of this cohort is interesting for a number of reasons. In
animal studies maternal nutrition at the time of conception is
observed to inﬂuence gender speciﬁc survival of fetuses, witha relative excess of male offspring born at times of nutritional
plenty [38]. In humans however this phenomenon is debated
[39,40]. In addition gender differences in placental function have
not been fully investigated and this study is underpowered to fully
answer this question. Whilst there is a preponderance of male
fetuses in the obese cohort, our subanalysis of fetal gender sug-
gests that the predominant effect of maternal obesity on fetal
growth is observed in female offspring whilst birth weights and
IBRs of the male offspring were not different between normal-BMI
and obese groups. It remains therefore a possibility that the
observed differences in placental arterial function between obese
and normal-BMI women’s offspring may be confounded by the
observed gender imbalance, with blunting of placental arterial
vasodilation in order to limit fetal overgrowth that may be more
marked amongst male fetuses. There is certainly a growing evi-
dence base suggesting that male fetuses may be more susceptible
to certain pregnancy complications, with a higher rate of intra-
uterine growth and therefore higher in utero nutrient demands
which may fail to be met by a dysfunctional placenta [41]. Future
studies are required both to establish whether fetal gender in-
ﬂuences placental arterial function in health and in disease, and
also to establish whether sex selection occurs in humans.
Whilst ﬁrst trimester maternal BMI has been shown to accu-
rately reﬂect maternal adiposity [15], BMI  30 kg/m2 may be
viewed as a relatively arbitrary cut off to deﬁne those at risk of
obesity-related health problems. Indeed in some populations,
notably South East Asian communities, the risk of obesity-related
adverse health outcome accelerates at much lower BMI levels
than for Caucasian women [42]. We recommend that in order to
better understand the relationship of obesity to pregnancy out-
come, longitudinal cohort studies should be conducted to examine
maternal adiposity and nutrition not only using ﬁrst trimester BMI
but also with pre-pregnancy weight, BMI, waist-hip ratio and
nutritional status and the change in adiposity across gestation.
This study of the effect of obesity and adipokines on placental
vascular function is not exhaustive and many questions relating to
the effect of obesity on the placenta remain unanswered, partic-
ularly regarding the mechanisms underlying such changes. Future
studies examining the impact of factors such as periconceptual and
gestational caloric intake, changes in maternal adiposity through-
out pregnancy and relating maternal/fetal circulating adipokine
concentrations to pregnancy outcome and placental vascular
function are recommended.
5. Conclusion
Placental vascular function is altered inwomenwho are obese at
the start of pregnancy, despite exclusion of maternal and fetal co-
morbidity. Although leptin incubation of CPAs from women of
normal-BMI altered vascular reactivity, the speciﬁc vascular proﬁle
observed in maternal obesity was not reproduced. The potential
role for other adipokines such as adiponectin, in the obese CPA
functional phenotype requires further study. The causes of obesity-
related placental vascular dysfunction are potential targets for
modulation in order to break the vicious cycle of maternal obesity
and its burden upon healthcare resources and society.
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